The LDN Shop
Visit our e-commerce website for Conferences, Webinars, Medical Membership, eBooks etc
Enkephalin Therapy Improves Relapsing-Remitting Multiple Sclerosis
From An Overview and Management of Multiple Chronic Conditions, Edited by Sevgi Akarsu
28 January 2020
https://www.intechopen.com/online-first/enkephalin-therapy-improves-relapsing-remitting-multiple-sclerosis
Off-label, Low-Dose Naltrexone for Refractory Chronic Low Back Pain
Pain Med
May 2014
https://europepmc.org/article/med/24967470
The Benefits of Low Dose Naltrexone
JewishLink
21 May 2020
https://jewishlink.news/monthly-sections/health-link-new/37942-the-benefits-of-low-dose-naltrexone
MS breakthrough: Cancer drug repairs damaged myelin nerve tissue in human trials first
The Herald
25 September 2020
https://www.heraldscotland.com/news/18748293.ms-breakthrough-cancer-drug-repairs-damaged-myelin-nerve-tissue-human-trials-first/
Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone
Behav Brain Res
01 Jan 2021
https://pubmed.ncbi.nlm.nih.gov/32905811/
[Met 5]-enkephalin preserves diffusion metrics in EAE mice (Abstract)
Brain Res Bull
December 2020
https://pubmed.ncbi.nlm.nih.gov/33141073/
Cameon LDN and Multiple Sclerosis (MS) (low dose naltrexone) from LDN Research Trust on Vimeo.
Cameon from the USA shares her story of going from 7 years in a wheelchair to walking, after taking Low Dose Naltrexone for 10 months.
Her speech is slow but improved as one of the symptoms he suffered from Multiple Sclerosis (MS).
Ulrich Lanius, PhD and Galyn Forster, MS, LPC - Opioid Antagonists and Traumatic Brain Injury (2017 Conference) (LDN, low dose naltrexone)
They begin their presentation by discussing Naltrexone and seizure activity, as demonstrated through clinical trials. They found that later dosage adjustments were helpful in reducing the cognitive effects.
Jarred Younger, PhD - Calming microglia: a future method for treating multiple sclerosis (2016 Conference) (LDN, low dose naltrexone)
Jarred Younger, PhD - The Ten Most Important Fibromyalgia Discoveries of 2016 and 2017 (2017 Conference) (LDN, low dose naltrexone)
People with rheumatological conditions are much more likely to have fibromyalgia than the general population, Lupus in particular was indicated to be the most likely rheumatological condition where fibromyalgia was also present.